+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
A

Actively Recruiting

Herpes simplex viruses HSV are carried by almost 90% of people and remain in the body for life, usually dormant. Reactivation occurs mainly when the immune system is weakened, causing mostly harmless cold sores but potentially serious infections like meningitis in immunocompromised individuals. This study is investigating whether treating HSV with acyclovir can improve survival in ventilated intensive care patients with pneumonia who have a high amount of HSV detected in their respiratory tract, as current evidence from retrospective studies is inconclusive. The trial compares two groups of ICU patients on mechanical ventilation with lower respiratory tract infection and HSV-1 detected in bronchoalveolar lavage BAL. One group receives intravenous acyclovir at 10 mgkg every 8 hours for up to 10 days or until ICU discharge, while the control group receives no antiviral therapy. The study is randomized and controlled to provide clear evidence on the effects of antiviral treatment in this patient population. Participants will be monitored for survival status at 30 days as the primary outcome. Secondary outcomes include ventilation-free days, vasopressor-free days, organ failure assessment scores, kidney function, length of ICU and hospital stay, quality of life measures, microbiological cure, and safety events. The study involves multiple assessments up to 180 days and tracks cost and adverse events, aiming to clarify the role of acyclovir therapy in improving outcomes for ventilated ICU patients with HSV-related pneumonia.

Age: 18Years +All GendersPhase 3
28 locations
C

Actively Recruiting

Atrial fibrillation is the most common heart rhythm disorder, increasing the risk of blood clots forming in the heart, especially in the left atrium. These clots can cause strokes if they travel to the brain. Patients with atrial fibrillation who have had an intracranial bleed bleeding in the brain are often treated with blood thinners to prevent stroke, but these medications can increase bleeding risk. This study compares two treatment methods to prevent strokes in such patients blood thinners and a device that closes off the left atrial appendage of the heart. The study randomly assigns participants to one of two groups. One group receives a device called Watchman or Watchman FLX to close the left atrial appendage through a minimally invasive procedure, followed by short-term blood thinning medication. The other group receives standard oral blood thinners as per current guidelines. Only approved drugs and devices are used. The trial aims to provide data to help doctors manage patients with atrial fibrillation who have experienced brain bleeds. Participants are followed for up to three years after randomization. Researchers monitor for events such as death from cardiovascular causes, stroke, systemic embolism, and bleeding episodes. Assessments include imaging during the procedure and regular follow-up visits to track health outcomes. The main measure is event-free survival without these complications. This long-term follow-up helps evaluate the safety and effectiveness of each treatment approach in preventing strokes and bleeding.

Age: 18Years +All GendersPhase Not Applicable
39 locations
D

Actively Recruiting

Researchers are studying dementia and mild cognitive impairment in Bavaria, focusing on people living at home with these conditions and their family caregivers. This study aims to improve understanding of the complexity, progression, and care needs of dementia in both urban and rural areas. The research includes people with mild cognitive impairment and mild to moderate dementia as defined by ICD-10 codes and is conducted through a multicenter, prospective, longitudinal registry. Participants include those with mild cognitive impairment or dementia and their family caregivers. Before joining, cognitive tests such as the Mini Mental State Examination and Montreal Cognitive Assessment are used to assess suitability. Participants are interviewed face-to-face at the start, after 6 months, 12 months, and then annually. Recruitment is through various institutions involved in dementia care, including clinics, counseling centers, and outpatient and inpatient facilities across Bavaria. During the study, participants provide detailed information on demographics, health, social and care situations, cognitive assessments, and quality of life measures at multiple timepoints over several years. Researchers collect data on medical history, medication use, cognitive function, social support, internet use, mobility, caregiver burden, and more. This long-term observation helps track changes and care needs up to ten years, with regular follow-up interviews and assessments throughout the study.

All AgesAll Genders
12 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
O

Actively Recruiting

Researchers are evaluating how well Fruquintinib works to treat adults with metastatic colorectal cancer who have already received standard treatments. This observational study in Germany aims to analyze patient response to Fruquintinib in routine clinical practice, focusing on survival, safety, medical care usage, and quality of life. The study also includes a translational research project to link clinical data with biomarkers for better understanding treatment benefit. Participants receive Fruquintinib as determined by their treating physician according to approved guidelines. The study collects real-world data from about 150 patients across various healthcare settings. Archival tumor tissue and blood samples are gathered to study biomarkers and circulating tumor DNA, which may indicate treatment response. During the study, participants health and treatment effects are monitored through clinical data and biomarker analysis. Researchers measure disease control, response rates, survival, adverse events, quality of life, treatment duration, hospitalizations, and other outcomes up to 33 months. The study provides insight into Fruquintinibs use and impact in everyday care over an average of 6 to 7 months of treatment and extended follow-up.

Age: 18Years +All Genders
42 locations

1-10 of 18

1